What does Janssen-Cilag do?

Janssen-Cilag is a wholesaler in Beerse. Public Limited, started on 6 August 1975, 2 establishments.

What is the address of Janssen-Cilag?

The registered office of Janssen-Cilag is located at Antwerpseweg 15-17, 2340 Beerse.

Is Janssen-Cilag still active?

Yes. According to the CBE (29 October 2026) Janssen-Cilag is active, legal situation “Normale toestand”, started on 6 August 1975.

Is Janssen-Cilag registered on Peppol?

Yes, Janssen-Cilag is registered on the Peppol network with ID 0208:0415283427.

What is the enterprise number of Janssen-Cilag?

The enterprise number of Janssen-Cilag is BE0415283427.

When was Janssen-Cilag founded?

Janssen-Cilag was founded on 6 August 1975.

Who are the directors of Janssen-Cilag?

According to the 2025 annual accounts, the directors of Janssen-Cilag are: Marleen Hoebus, Nicoleta - Roxana Botea, Luc van Oevelen.

Is Janssen-Cilag a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 6 August 1975; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account; 2 establishments in the CBE.

How much profit did Janssen-Cilag make in 2025?

Janssen-Cilag posted a profit after taxes of € 30,854,715 in financial year 2025.

What is the revenue of Janssen-Cilag?

In its most recent annual accounts (2025), Janssen-Cilag reported revenue of € 675,277,536.

How much does an employee at Janssen-Cilag earn?

The average wage cost per full-time employee at Janssen-Cilag was € 190,300 in 2025: staff costs of € 39.5 million for 207.6 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Janssen-Cilag have?

According to the 2025 annual accounts, Janssen-Cilag has 207.6 full-time equivalents (FTE).

Janssen-Cilag (Public Limited) - Beerse - BE0415283427

Dossier Janssen-Cilag, printed on 29 October 2026 from databakkes.be/en/0415283427/janssen-cilag. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Janssen-Cilag from Beerse, company number BE0415283427, closed financial year 2025 with a result of € 30.9 million after tax. For that financial year Janssen-Cilag recorded revenue of € 675.3 million and equity of € 101.3 million. Compared with financial year 2024, the result moved from € 15 million to € 30.9 million. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 6, 2026.

What it is worth Growing

€ 101.3 million

▲ 26% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 30.9 million

▲ 106% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 7.3 million

▲ 29% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 10 million paid out

32 % of the profit went to the shareholders, mostly to Janssen Pharmaceutica NV (100 % of the shares). That is where the money ends up.

People and assets in 2025

Full-time equivalents

207.6

▼ 8.5 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost Staff costs are payroll only. Director pay sits with services and miscellaneous goods: € 38.4 million in 2025, together with rent, insurance, accountants and other services. The accounts do not split that further.

€ 39.5 million

▲ 8% vs 2024

€ 190,300 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 23,050

▼ 40% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 33 million

▼ 59% vs 2024

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 32 days on average.

Taxes and wages

€ 17.4 million

▼ 22% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 556,479,612 Revenue 2022: € 556,479,612 First fiscal year in the series	€ 594,441,095 Revenue 2023: € 594,441,095 ▲ 7% vs 2022 (€ 556,479,612) Favourable step	€ 624,672,769 Revenue 2024: € 624,672,769 ▲ 5% vs 2023 (€ 594,441,095) Favourable step	€ 675,277,536 Revenue 2025: € 675,277,536 ▲ 8% vs 2024 (€ 624,672,769) Favourable step	▲ 8%
Profit after taxes	€ 12,749,511 Profit after taxes 2022: € 12,749,511 First fiscal year in the series	€ 20,911,183 Profit after taxes 2023: € 20,911,183 ▲ 64% vs 2022 (€ 12,749,511) Favourable step	€ 14,977,639 Profit after taxes 2024: € 14,977,639 ▼ 28% vs 2023 (€ 20,911,183) Unfavourable step	€ 30,854,715 Profit after taxes 2025: € 30,854,715 ▲ 106% vs 2024 (€ 14,977,639) Favourable step	▲ 106%
Equity	€ 44,556,956 Equity 2022: € 44,556,956 First fiscal year in the series	€ 65,468,139 Equity 2023: € 65,468,139 ▲ 47% vs 2022 (€ 44,556,956) Favourable step	€ 80,445,779 Equity 2024: € 80,445,779 ▲ 23% vs 2023 (€ 65,468,139) Favourable step	€ 101,300,494 Equity 2025: € 101,300,494 ▲ 26% vs 2024 (€ 80,445,779) Favourable step	▲ 26%
Total debts	€ 93,299,797 Total debts 2022: € 93,299,797 First fiscal year in the series	€ 129,780,083 Total debts 2023: € 129,780,083 ▲ 39% vs 2022 (€ 93,299,797) Unfavourable step	€ 103,877,754 Total debts 2024: € 103,877,754 ▼ 20% vs 2023 (€ 129,780,083) Favourable step	€ 76,236,073 Total debts 2025: € 76,236,073 ▼ 27% vs 2024 (€ 103,877,754) Favourable step	▼ 27%
Cash	€ 10,582,868 Cash 2022: € 10,582,868 First fiscal year in the series	€ 6,130,045 Cash 2023: € 6,130,045 ▼ 42% vs 2022 (€ 10,582,868) Unfavourable step	€ 5,706,282 Cash 2024: € 5,706,282 ▼ 7% vs 2023 (€ 6,130,045) Unfavourable step	€ 7,344,121 Cash 2025: € 7,344,121 ▲ 29% vs 2024 (€ 5,706,282) Favourable step	▲ 29%
Retained profit	€ 31,031,215 Retained profit 2022: € 31,031,215 First fiscal year in the series	€ 51,942,398 Retained profit 2023: € 51,942,398 ▲ 67% vs 2022 (€ 31,031,215) Favourable step	€ 66,920,038 Retained profit 2024: € 66,920,038 ▲ 29% vs 2023 (€ 51,942,398) Favourable step	€ 87,774,753 Retained profit 2025: € 87,774,753 ▲ 31% vs 2024 (€ 66,920,038) Favourable step	▲ 31%
Dividend	€ 23,000,000 Dividend 2022: € 23,000,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 23,000,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 10,000,000 Dividend 2025: € 10,000,000 Unchanged (€ 0) Unchanged
Balance sheet total	€ 144,101,868 Balance sheet total 2022: € 144,101,868 First fiscal year in the series	€ 201,637,354 Balance sheet total 2023: € 201,637,354 ▲ 40% vs 2022 (€ 144,101,868) Unchanged	€ 195,660,081 Balance sheet total 2024: € 195,660,081 ▼ 3% vs 2023 (€ 201,637,354) Unchanged	€ 188,042,233 Balance sheet total 2025: € 188,042,233 ▼ 4% vs 2024 (€ 195,660,081) Unchanged	▼ 4%
Employees (FTE)	238.5 Employees (FTE) 2022: 238.5 First fiscal year in the series	230.4 Employees (FTE) 2023: 230.4 ▼ 8.1 vs 2022 (238.5) Unchanged	216.1 Employees (FTE) 2024: 216.1 ▼ 14.3 vs 2023 (230.4) Unchanged	207.6 Employees (FTE) 2025: 207.6 ▼ 8.5 vs 2024 (216.1) Unchanged	▼ 8.5

Key figures of Janssen-Cilag, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Janssen-Cilag?

What happened at Janssen-Cilag in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2030 Nicoleta - Roxana Botea stepped down as director. NBB
2030 Luc van Oevelen stepped down as director. NBB
2027 Marleen Hoebus stepped down as director. NBB
Jul 6, 2026 New annual accounts for financial year 2025: profit of € 30.9 million (▲ 106% vs 2024). Source: NBB ↗
2024 Nicoleta - Roxana Botea became a director. NBB
2024 Luc van Oevelen became a director. NBB
2021 Marleen Hoebus became a director. NBB
Aug 6, 2012 New establishment in Machelen (Brab.). KBO

In short

From € 12.7 million profit in 2022 to € 30.9 million profit in 2025.

Paid € 28 million in corporate taxes since 2022.

Best year ever: 2025, with € 30.9 million profit.

Paid out € 33 million in dividends to the owners in total.

Original PDFs at the National Bank ↗

Management

Janssen Pharmaceutica NV 100%

Johnson & Johnson International 0%

Janssen-Cilag

The shares are held by Janssen Pharmaceutica NV (100%) and Johnson & Johnson International (0%).

Directors

According to the 2025 annual accounts

Marleen Hoebus

Managing director

since 2021 · until 2027

Nicoleta - Roxana Botea

Managing director

since 2024 · until 2030

Luc van Oevelen

Managing director

since 2024 · until 2030

Shareholders

Janssen Pharmaceutica NV

100%

Johnson & Johnson International

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Antwerpseweg 15-17

2340 Beerse

2.213.221.482

Leonardo da Vincilaan 15

1831 Machelen (Brab.)

Active since 6 August 2012

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0415.283.427

VAT number

BE 0415.283.427

Registered office

Antwerpseweg 15-17, 2340 Beerse

Names & denominations

Johnson & Johnson, J&J, Johnson & Johnson Innovative Medicine, J&J Innovative Medicine · Janssen-Cilag

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

6 August 1975

Peppol

Active · Active since 23 Mar 2026

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗

Janssen-Cilag

Financials

What happened to Janssen-Cilag?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions